IPP Bureau
Roche gets FDA approval for Alecensa in early lung cancer
By IPP Bureau - April 22, 2024
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
Vertex announces advancements of Suzetrigine in acute and neuropathic pain
By IPP Bureau - April 22, 2024
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Jubilant Pharmova to close manufacturing operations of Solid dosage formulation facility of Jubilant Cadista USA
By IPP Bureau - April 19, 2024
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Shilpa Medicare launches Pemetrexed injection
By IPP Bureau - April 19, 2024
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents
Fresenius Kabi USA flies complaint against NATCO Pharma
By IPP Bureau - April 19, 2024
Natco Pharma intends to defend the matter accordingly
AIC-CCMB signs agreement for placement of equipment with Thermo Fisher Scientific to help advance innovation in India
By IPP Bureau - April 19, 2024
Thermo Fisher has equipped this Centre for Innovation with state-of-the-art platforms such as CellInsight CX7 LZR Pro High Content Screening Platform
PharmaLytica 2024 to draw 200+ exhibitors
By IPP Bureau - April 19, 2024
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
Dr. Reddy’s launches integrated care plan to manage irritable bowel syndrome
By IPP Bureau - April 19, 2024
Around 7% of the Indian population suffers from IBS
Biocon inks agreement for Ozempic commercialization in Brazil with Biomm
By IPP Bureau - April 19, 2024
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Jubilant Pharmova’s Roorkee unit gets VAI status
By IPP Bureau - April 18, 2024
FDA has concluded that this inspection is 'closed'
GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
By IPP Bureau - April 17, 2024
Submission based on results from pivotal phase III trial showing all primary endpoints met
Caplin Steriles gets USFDA approval for Ofloxacin ophthalmic solution
By IPP Bureau - April 17, 2024
Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers
USFDA grants ODD to NM5072 for treatment of Paroxysmal Nocturnal Hemoglobinuria
By IPP Bureau - April 17, 2024
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
AbbVie announces late-breaking data at AAN supporting efficacy of Atogepant for preventive treatment of migraine
By IPP Bureau - April 17, 2024
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
AstraZeneca’s Imfinzi plus chemotherapy doubled overall survival rate for patients with advanced biliary tract cancer
By IPP Bureau - April 17, 2024
Longest survival follow-up ever reported for immunotherapy treatment in this setting
